NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
1,190 trialsNCT06487715 2024-07-05
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06353581 2024-04-09
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
Yonsei University
Phase 2 Unknown
NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Unknown
NCT04543695 2024-03-26
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06322563 2024-03-21
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04249739 2024-03-13
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
Samsung Medical Center
Phase 2 Unknown
NCT03951337 2024-03-12
64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
Institut Cancerologie de l'Ouest
Phase 2 Unknown
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT06301828 2024-03-08
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT06280690 2024-02-29
SGM-T1
Leiden University Medical Center
Phase 2 Unknown
NCT06284746 2024-02-29
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
NCT05122091 2024-02-26
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
Guangxi Medical University
Phase 2 Unknown
NCT05371223 2024-02-26
Nab-PIPAC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
NCT04096417 2024-02-21
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
Phase 2 Unknown
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT06262581 2024-02-16
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
Sun Yat-sen University
Phase 2 Unknown
NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06250894 2024-02-09
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04151277 2024-02-08
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
University of Glasgow
Phase 2 Unknown
NCT05980689 2024-02-07
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05933980 2024-02-06
REGOTORICOX
Sun Yat-sen University
Phase 2 Unknown
NCT06239870 2024-02-02
ESTIMATE
Yunnan Cancer Hospital
Phase 2 Unknown
NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT03503630 2024-01-31
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
American University of Beirut Medical Center
Phase 2 Unknown
NCT06231017 2024-01-30
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT04617457 2024-01-12
HOLIPANC
University of Cologne
Phase 2 Unknown
NCT06198465 2024-01-10
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
Xijing Hospital
Phase 2 Unknown
NCT06192784 2024-01-09
CCGLC-012
Tongji Hospital
Phase 2 Unknown
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT05626569 2024-01-03
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Sun Yat-sen University
Phase 2 Unknown
NCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT06171854 2024-01-02
ABACO
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT04329429 2023-12-20
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
RemeGen Co., Ltd.
Phase 2 Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06153368 2023-12-07
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown